JP2016108250A5 - - Google Patents

Download PDF

Info

Publication number
JP2016108250A5
JP2016108250A5 JP2014244421A JP2014244421A JP2016108250A5 JP 2016108250 A5 JP2016108250 A5 JP 2016108250A5 JP 2014244421 A JP2014244421 A JP 2014244421A JP 2014244421 A JP2014244421 A JP 2014244421A JP 2016108250 A5 JP2016108250 A5 JP 2016108250A5
Authority
JP
Japan
Prior art keywords
nucleic acid
stranded nucleic
composition according
adjuvant composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014244421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016108250A (ja
JP6453063B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2014244421A external-priority patent/JP6453063B2/ja
Priority to JP2014244421A priority Critical patent/JP6453063B2/ja
Priority to CN201580065778.3A priority patent/CN106999573B/zh
Priority to CA2969024A priority patent/CA2969024C/en
Priority to AU2015356078A priority patent/AU2015356078B2/en
Priority to US15/531,671 priority patent/US10105385B1/en
Priority to EP15865520.9A priority patent/EP3228322B8/en
Priority to PCT/JP2015/083825 priority patent/WO2016088784A1/ja
Publication of JP2016108250A publication Critical patent/JP2016108250A/ja
Publication of JP2016108250A5 publication Critical patent/JP2016108250A5/ja
Publication of JP6453063B2 publication Critical patent/JP6453063B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014244421A 2014-12-02 2014-12-02 アジュバント組成物 Active JP6453063B2 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2014244421A JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物
US15/531,671 US10105385B1 (en) 2014-12-02 2015-12-01 Adjuvant composition
CA2969024A CA2969024C (en) 2014-12-02 2015-12-01 Adjuvant composition
AU2015356078A AU2015356078B2 (en) 2014-12-02 2015-12-01 Adjuvant composition
CN201580065778.3A CN106999573B (zh) 2014-12-02 2015-12-01 佐剂组合物
EP15865520.9A EP3228322B8 (en) 2014-12-02 2015-12-01 Adjuvant composition
PCT/JP2015/083825 WO2016088784A1 (ja) 2014-12-02 2015-12-01 アジュバント組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014244421A JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物

Publications (3)

Publication Number Publication Date
JP2016108250A JP2016108250A (ja) 2016-06-20
JP2016108250A5 true JP2016108250A5 (enExample) 2018-01-25
JP6453063B2 JP6453063B2 (ja) 2019-01-16

Family

ID=56091725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014244421A Active JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物

Country Status (7)

Country Link
US (1) US10105385B1 (enExample)
EP (1) EP3228322B8 (enExample)
JP (1) JP6453063B2 (enExample)
CN (1) CN106999573B (enExample)
AU (1) AU2015356078B2 (enExample)
CA (1) CA2969024C (enExample)
WO (1) WO2016088784A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017221076A1 (en) * 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
KR20190034210A (ko) 2016-07-27 2019-04-01 가부시키가이샤 츠기츠기세다이 이노베이숀 가이하츠 암 면역 아쥬반트
EP3509629A1 (en) * 2016-09-06 2019-07-17 H. Hoffnabb-La Roche Ag Mhc-bound peptide arrays and methods of use thereof
EP4632069A1 (en) 2022-12-05 2025-10-15 Aomori Yamada Gakuen Educational Corporation Nucleic acid adjuvant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064358A2 (en) * 1998-03-26 2001-01-03 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
WO2012014945A1 (ja) * 2010-07-28 2012-02-02 国立大学法人北海道大学 アジュバント活性を有する新規核酸およびその利用
CN102000330B (zh) * 2010-09-14 2012-08-29 中国人民解放军第二军医大学 一种核酸疫苗佐剂及其构建方法

Similar Documents

Publication Publication Date Title
JP2016526529A5 (enExample)
JP2016525888A5 (enExample)
EP4501318A3 (en) Nucleic acid vaccines
JP2016528887A5 (enExample)
JP2016195614A5 (enExample)
JP2017502668A5 (enExample)
EP3252172A3 (en) Fast hybridization for next generation sequencing target enrichment
EP4328322A3 (en) Probe library construction
JP2019515674A5 (enExample)
JP2015133993A5 (enExample)
WO2015081229A3 (en) Selective amplification of nucleic acid sequences
EP4310196A3 (en) Methods and compositions for manipulating nucleic acids
JP2013005803A5 (enExample)
IL250539A0 (en) Nucleotides modified for nucleic acid synthesis, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes
WO2015089511A3 (en) Modified nucleic acid molecules and uses thereof
JP2016513950A5 (enExample)
HK1245800A1 (zh) 被取代的核苷、核苷酸及其类似物
BR112015022522A2 (pt) engenharia de genomas de planta usando sistemas crispr/cas
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
NZ712727A (en) Compositions and methods of nucleic acid-targeting nucleic acids
MX356792B (es) Elementos de regulacion de plantas y sus usos.
WO2015026845A3 (en) Nucleotide analogs
JP2016104015A5 (enExample)
JP2012223202A5 (enExample)
MX374553B (es) Derivado de ácido nucleico que tiene actividad inmunoestimuladora.